Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,994 shares of the biopharmaceutical company’s stock after acquiring an additional 1,523 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Regeneron Pharmaceuticals were worth $5,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Daiwa Securities Group Inc. grew its stake in Regeneron Pharmaceuticals by 12.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock worth $21,428,000 after buying an additional 2,234 shares during the last quarter. Summit Trail Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 10.6% in the third quarter. Summit Trail Advisors LLC now owns 1,390 shares of the biopharmaceutical company’s stock valued at $1,461,000 after acquiring an additional 133 shares during the period. Alpha DNA Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 80.5% during the third quarter. Alpha DNA Investment Management LLC now owns 630 shares of the biopharmaceutical company’s stock worth $662,000 after acquiring an additional 281 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 127.3% in the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 28 shares during the period. Finally, Swedbank AB raised its position in Regeneron Pharmaceuticals by 10.1% in the 3rd quarter. Swedbank AB now owns 149,363 shares of the biopharmaceutical company’s stock valued at $157,016,000 after purchasing an additional 13,705 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.9 %

REGN stock opened at $738.00 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company’s 50 day simple moving average is $945.07 and its 200-day simple moving average is $1,027.53. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The firm has a market capitalization of $81.10 billion, a PE ratio of 18.26, a P/E/G ratio of 2.84 and a beta of 0.15.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Finally, Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.48% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.